NCT01714154View on ClinicalTrials.gov

A Safety And Pharmacokinetic Study of Setrobuvir Alone and In Combination With Ritonavir-Boosted Danoprevir in Subjects With Mild Hepatic Impairment Compared to Healthy Controls

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions
Healthy Volunteer
Interventions
DRUG

danoprevir

100 mg orally every 12 hours

DRUG

ritonavir

100 mg orally every 12 hours

DRUG

setrobuvir

200 mg orally every 12 hours

Trial Locations (3)

1076

Budapest

8230

Balatonfüred

01-201

Warsaw

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01714154 - A Safety And Pharmacokinetic Study of Setrobuvir Alone and In Combination With Ritonavir-Boosted Danoprevir in Subjects With Mild Hepatic Impairment Compared to Healthy Controls | Biotech Hunter | Biotech Hunter